Das Stadtspital Triemli oder Triemli in Zürich ist das drittgrösste Krankenhaus im Kanton Zürich und eine Dienstabteilung des Gesundheits- und Umweltdepartements der Stadt Zürich.

During the past decade, Stadtspital Triemli conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Stadtspital Triemli" #1 sponsor was "Swiss Group for Clinical Cancer Research" with 11 trials, followed by "Abbott Medical Devices" with 3 trials sponsored, "Biotronik SE & Co. KG" with 3 trials sponsored, "University Hospital Inselspital, Berne" with 3 trials sponsored and "University of Zurich" with 3 trials sponsored. Other sponsors include 13 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Stadtspital Triemli" #1 collaborator was "Triemli Hospital" with 4 trials as a collaborator, "Cantonal Hospital of St. Gallen" with 3 trials as a collaborator, "Cancer Trials Ireland" with 2 trials as a collaborator, "Hoffmann-La Roche" with 2 trials as a collaborator and "Janssen-Cilag Ltd." with 2 trials as a collaborator. Other collaborators include 46 different institutions and companies that were collaborators in the rest 51 trials.

According to Clinical.Site data, the most researched conditions in "Stadtspital Triemli" are "Prostate Cancer" (4 trials), "Atrial Fibrillation" (2 trials), "Breast Cancer" (2 trials), "Coronary Artery Disease" (2 trials) and "Metastatic Colorectal Cancer" (2 trials). Many other conditions were trialed in "Stadtspital Triemli" in a lesser frequency.

Most popular intervention types in "Stadtspital Triemli" are "Drug" (21 trials), "Device" (8 trials), "Other" (7 trials), "Radiation" (4 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Ibrutinib" (3 trials), "Metformin" (2 trials), "Obinutuzumab" (2 trials), "Placebo" (2 trials) and "Rituximab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Stadtspital Triemli" are 34 trials for "All" genders, 4 trials for "Male" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Stadtspital Triemli". 1 are not yet recruiting, 10 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Stadtspital Triemli, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Stadtspital Triemli, 2 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 7 trials that are defined as “Not Applicable".